Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
Launched by OTSUKA PHARMACEUTICAL CO., LTD. · Apr 17, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the long-term safety and effectiveness of a medication called AJOVY, which is used to help manage migraine disorders. Researchers want to see how AJOVY performs when used in real-life situations, particularly looking for any potential heart-related issues that might arise from its use. They will also gather information about how well the medication works for patients over time.
If you're between the ages of 65 and 74, you may be eligible to participate in this trial, as long as you do not have a known allergy to any of AJOVY's ingredients. Participants in the study will receive AJOVY and be monitored for safety and effectiveness over an extended period. This is an important opportunity to contribute to our understanding of how this medication can help improve the lives of people with migraines.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • -
- Exclusion Criteria:
- • patients with a known hypersensitivity to components of AJOVY
About Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company headquartered in Tokyo, Japan, dedicated to the research, development, and commercialization of innovative pharmaceuticals and nutraceuticals. Founded in 1964, Otsuka focuses on addressing unmet medical needs across various therapeutic areas, including psychiatry, neurology, oncology, and cardiovascular health. With a commitment to advancing healthcare through scientific innovation, Otsuka leverages its expertise in drug development and strategic partnerships to deliver groundbreaking therapies that improve patients' quality of life. The company's dedication to sustainability and ethical practices underscores its mission to contribute positively to global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Osaka, , Japan
Patients applied
Trial Officials
Yasuhiko Fukuta, PhD
Study Director
Otsuka Pharmaceutical Co., Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials